title: An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix.
abstract: Thirty-two evaluable patients with squamous cell cancer of the cervix were treated with i.v. paclitaxel 250 mg/m2 over 3 h every 21 days. They received standard premedications and granulocyte colony stimulating factor (G-CSF) support (5 micrograms/kg/day). Median (range) age was 49 (29-81) years and performance status Zubrod was 1 (0-2). One patient had a complete response and seven patients had a partial response (25%, 95% CI 8-38%). The median survival was 7.3 months. Granulocytopenia was brief and non-cumulative. G-CSF was used for a median (range) of 8 (1-15) days per cycle.
  
  
  CONCLUSIONS
  paclitaxel is active in patients with squamous cell cancer of the cervix and is well tolerated in this dose schedule with G-CSF support.
authors.affiliation: University of Texas MD Anderson Cancer Center, Section of Gynecologic Medical Oncology, Houston 77030-4095, USA.
authors.forename: A P
authors.initials: AP
authors.lastname: Kudelka
authors.forename: R
authors.initials: R
authors.lastname: Winn
authors.forename: C L
authors.initials: CL
authors.lastname: Edwards
authors.forename: G
authors.initials: G
authors.lastname: Downey
authors.forename: H
authors.initials: H
authors.lastname: Greenberg
authors.forename: S R
authors.initials: SR
authors.lastname: Dakhil
authors.forename: R S
authors.initials: RS
authors.lastname: Freedman
authors.forename: S
authors.initials: S
authors.lastname: LoCoco
authors.forename: J
authors.initials: J
authors.lastname: Umbreit
authors.forename: J E
authors.initials: JE
authors.lastname: Delmore
authors.forename: S
authors.initials: S
authors.lastname: Arbuck
authors.forename: E
authors.initials: E
authors.lastname: Loyer
authors.forename: P
authors.initials: P
authors.lastname: Gacrama
authors.forename: R
authors.initials: R
authors.lastname: Fueger
authors.forename: J J
authors.initials: JJ
authors.lastname: Kavanagh
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018579:Patient Selection; D012008:Recurrence; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D016179:Granulocyte Colony-Stimulating Factor; D017239:Paclitaxel